CliffBio
biologic

Reblozyl

luspatercept-aamt

Loss of exclusivityNovember 2031projected — 12-year biologic exclusivity estimate
CompanyCelgene Corporation, a Bristol-Myers Squibb Company

Drug detail

Brand nameReblozyl
Active ingredientluspatercept-aamt
Strength75MG/VIAL
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2019
Marketing statusRx

More from Celgene Corporation, a Bristol-Myers Squibb Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Reblozyl patent cliff — loss of exclusivity November 2031 | CliffBio